ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Maraviroc

Also written as “Maraviroc (UK-427,857)”, “maraviroc” and “Maraviroc + Fosamprenavir/ritonavir”.

Its studies are mostly in Acquired Immunodeficiency Syndrome · HIV Infections · Post-Acute COVID-19 Syndrome · Infections · Arthritis, Rheumatoid, led by 4 companies.

Drug pageMaraviroc: every studyAll 118 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 4, since Apr 23, 200826 company-led studies, 1 open or runningNext primary completion: Dec 1, 2026 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
GlaxoSmithKline220 open or runningphase 4since Apr 23, 2008Dec 6, 2004none ahead
Pfizerits history only20 open or runningphase 2since Jan 25, 2007Jan 25, 2007none ahead
HealthBioits history only11 open or runningphase 3since May 7, 2025May 7, 2025Dec 1, 2026phase 3 · NCT06974084
Population Councilits history only10 open or runningphase 1since Jan 20, 2015Jan 20, 2015none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of GlaxoSmithKline only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 8 studies since Dec 6, 2004.

  1. Jul 15, 2008Phase 4 study in Acquired Immunodeficiency SyndromeNCT00717067 · 30 enrolled · Germany
  2. Jul 18, 2008Phase 3 study in Acquired Immunodeficiency SyndromeNCT00719823
  3. Oct 29, 2008Phase 4 study in Hepatitis BNCT00782301 · United States, Canada, Poland
  4. Nov 12, 2008Phase 2 study in Acquired Immunodeficiency SyndromeNCT00791700 · 103 enrolled · United States, Brazil, Italy and more
  5. Jan 12, 2009Phase 1 study in Acquired Immunodeficiency SyndromeNCT00821535 · 12 enrolled · Singapore
  6. Jan 21, 2009Phase 2 study in Human Immunodeficiency Virus-1NCT00827112 · 129 enrolled · United States, Germany, Spain
  7. Jan 22, 2010Phase 1 study in HIV InfectionsNCT01056874 · 12 enrolled · Singapore
  8. Jun 7, 2010Phase 1 study in Acquired Immunodeficiency SyndromeNCT01140412 · 14 enrolled · Singapore
  9. Feb 3, 2011Phase 1 study in Acquired Immunodeficiency SyndromeNCT01290211 · 28 enrolled · Belgium
  10. Mar 22, 2011Phase 4 study in HIV InfectionsNCT01327547 · 138 enrolled · United States, Czechia, France and more
  11. Apr 27, 2011Phase 3 study in Acquired Immunodeficiency SyndromeNCT01345630 · 813 enrolled · United States, Australia, Austria and more
  12. May 10, 2012Phase 1 study in HealthyNCT01597895 · 14 enrolled · Belgium
  13. Jun 16, 2015Phase 1 study in InfectionsNCT02480894 · 112 enrolled · United States
  14. Oct 20, 2015Phase 1 study in Healthy SubjectsNCT02625207 · 47 enrolled · United States

TargetBeta

CCR5 →read by rule
“A C-C Chemokine Receptor Type 5 (CCR5) antagonist with activity against human immunodeficiency virus (HIV)”NCIt, by rule
“C-C chemokine receptor type 5 antagonist”ChEMBL 37, by rule

Other programs on CCR5

ProgramCompanyFurthest phaseStudies
leronlimabruleCytoDynphase 320

Studies

All 22 GlaxoSmithKline leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT02625207Healthy Subjects · United States1CompletedMar 26, 201647
NCT02480894Infections · United States1CompletedSep 21, 2015112
NCT01597895Healthy · Belgium1CompletedAug 201214
NCT01345630Acquired Immunodeficiency Syndrome · United States, Australia, Austria and more3TerminatedAug 2013813
NCT01327547HIV Infections · United States, Czechia, France and more4CompletedApr 23, 2013138
NCT01290211Acquired Immunodeficiency Syndrome · Belgium1CompletedJun 201128
NCT01140412Acquired Immunodeficiency Syndrome · Singapore1TerminatedOct 201014
NCT01056874HIV Infections · Singapore1CompletedApr 201012
NCT00827112Human Immunodeficiency Virus-1 · United States, Germany, Spain2CompletedJul 2010129
NCT00821535Acquired Immunodeficiency Syndrome · Singapore1CompletedMay 200912
NCT00791700Acquired Immunodeficiency Syndrome · United States, Brazil, Italy and more2UNKNOWNApr 14, 2015103
NCT00782301Hepatitis B · United States, Canada, Poland4WithdrawnFeb 20100
NCT00719823Acquired Immunodeficiency Syndrome3WithdrawnMay 20100
NCT00717067Acquired Immunodeficiency Syndrome · Germany4CompletedNov 200830
NCT00666705Healthy · United States4CompletedMar 200818
NCT00643643HIV Infections · Germany, Netherlands, United Kingdom2CompletedJun 200341
NCT00634959HIV Infections · United States, Germany, United Kingdom2Completed37
NCT00496782HIV Infections · United States, Canada1TerminatedOct 200816
NCT00478231Acquired Immunodeficiency Syndrome · Brazil3CompletedAug 2010209
NCT00426660HIV Infections · United States, Argentina, Australia and more3CompletedJun 20101,047
NCT00098722HIV Infections · United States, Australia, Belgium and more3CompletedApr 2007474
NCT00098293Acquired Immunodeficiency Syndrome · United States, Argentina, Australia and more3CompletedApr 2007916

How it is read

Names in the registry

  • “Maraviroc”, 23 entries
  • “Maraviroc (UK-427,857)”, 8 entries
  • “maraviroc”, 5 entries
  • “Maraviroc + Fosamprenavir/ritonavir”, 4 entries
  • “Maraviroc +PF-03716539”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.